Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / GRCL - Gracell partners with Lonza to manufacture CAR-T cell candidates in U.S.

GRCL - Gracell partners with Lonza to manufacture CAR-T cell candidates in U.S.

Gracell Biotechnologies Inc.
Gracell Biotechnologies (GRCL) has signed a Manufacturing Service Agreement with Lonza (LZAGY) for clinical manufacturing of Gracell's CAR-T cell product candidates in the U.S.Lonza is an ‘ideal strategic collaborator for advancing our pioneering, proprietary FasTCAR platform globally," noted William Wei Cao, CEO of Gracell.“We look forward to a strategic relationship with Lonza to support IND-filing and clinical manufacturing in the U.S," added Martina Sersch, Chief Medical Officer of Gracell.Gracell’s lead program for GC012F, a BCMA/CD19 dual-targeting CAR-T therapy to treat multiple myeloma is manufactured on Gracell's proprietary FasTCAR technology platform.

For further details see:

Gracell partners with Lonza to manufacture CAR-T cell candidates in U.S.
Stock Information
Company Name: Gracell Biotechnologies Inc.
Stock Symbol: GRCL
Market: NASDAQ
Website: gracellbio.com
Menu
GRCL GRCL Quote GRCL Short GRCL News GRCL Articles GRCL Message Board
Get GRCL Alerts

News, Short Squeeze, Breakout and More Instantly...